RecruitingPhase 3NCT05561127

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel


Sponsor

GIE Medical

Enrollment

171 participants

Start Date

Nov 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

To determine the safety and efficacy of GIE Medical's ProTractX3™ TTS DCB for the treatment of recurrent benign bowel strictures.


Eligibility

Min Age: 22 Years

Inclusion Criteria5

  • Age ≥ 22
  • Diagnosis of symptomatic benign bowel stricture with at least 2 previous dilations.
  • Willing and able to complete protocol required follow up
  • Willing and able to provide written informed consent
  • Stricture length ≤ 5 cm

Exclusion Criteria20

  • Female subjects who are pregnant or breastfeeding or plan to get pregnant in next 12 months
  • Contraindication to endoscopy, anesthesia, or deep sedation.
  • Suspicion of malignant bowel stricture NOTE: Biopsy should be taken for every stricture during the initial endoscopy, however endoscopic balloon dilation may proceed without awaiting results if suspicion for malignancy is low in the opinion of the investigator.
  • Benign stricture due to extrinsic compression
  • Stricture is not amenable to standard balloon dilation (e.g. severe angulation, unable to pass guidewire, etc.)
  • Stricture complicated with abscess, fistula, perforation, leakage or varices
  • Stricture segment has moderate to severe active inflammation at the time of treatment. Moderate to severe inflammation is defined as any one of; ulcers >0.5cm in diameter, ulcerated surface >10%, affected (inflamed) surface >50%, marked erythema, absent vascular pattern, significant friability, or erosions
  • Multiple clinically significant strictures unable to be treated with a single balloon (i.e. total segment length must be ≤5cm) NOTE: Clinically significant strictures include those that are unable to be passed by the endoscope.
  • Received steroid injections into target stricture in the last 8 weeks
  • Stricture is not able to be dilated to ≥15mm in small bowel or ≥18mm in large bowel
  • Diagnosis of metastatic cancer of any type that is not considered in remission or non-metastatic cancer that may require radiation treatment in the pelvic region (e.g. prostate cancer)
  • Suspected perforation of gastrointestinal tract
  • Active systemic infection
  • Allergy to paclitaxel
  • Severe coagulation disorders or current use of anticoagulant or antiplatelet medication that cannot be safely managed per relevant societal guidelines
  • Chronic systemic steroid use (defined as greater than 10 mg/day) for any medical conditions unless subject is willing to undergo a 4-week washout and discontinue steroid use
  • Condition requiring treatment in urgent setting
  • Life expectancy of less than 24 months
  • Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety, such as recent myocardial infarction, severe pulmonary disease, bleeding diathesis, large thoracic aneurysm, pharyngeal or cervical deformity, etc.
  • Current participation in another pre-market drug or medical device clinical study unless in long term follow-up

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTGIE Medical ProTractX3 TTS DCB

The ProTractX3 Drug-coated balloon is a 0.035" guidewire compatible over-the-wire catheter.

OTHERControl

Standard of Care Endoscopic Dilation


Locations(33)

Honor Health

Scottsdale, Arizona, United States

University of California, Irvine

Irvine, California, United States

Gastro Care Institute

Lancaster, California, United States

Cedars Sinai

Los Angeles, California, United States

San Diego Gastroenterology

San Diego, California, United States

University of Colorado Anschutz

Aurora, Colorado, United States

University of Florida

Gainesville, Florida, United States

Borland-Groover

Jacksonville, Florida, United States

Research Associates of South Florida

Miami, Florida, United States

Hillcrest Medical Research

Orange City, Florida, United States

Orlando Health

Orlando, Florida, United States

Orlando Health

Orlando, Florida, United States

Gastroenterology Associates of Central Georgia, LLC

Macon, Georgia, United States

Rush University

Chicago, Illinois, United States

Kansas Gastroenterology, LLC

Wichita, Kansas, United States

University of Louisville

Louisville, Kentucky, United States

Tandem Clinical Research

Marrero, Louisiana, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Washington University

St Louis, Missouri, United States

Rutgers University

Piscataway, New Jersey, United States

New York Presbyterian Hospital- Columbia University Medical Center

New York, New York, United States

Lenox Hill Hospital

New York, New York, United States

University of North Carolina

Chapel Hill, North Carolina, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Einstein Medical Center

Philadelphia, Pennsylvania, United States

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Allegheny Health Network

Pittsburgh, Pennsylvania, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Baylor St. Luke's Medical Center

Houston, Texas, United States

The University of Utah

Salt Lake City, Utah, United States

Virginia Mason

Seattle, Washington, United States

Swedish Medical Center

Seattle, Washington, United States

West Virginia University

Morgantown, West Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05561127